** Celltrion 068270.KS and Samsung Biologics 207940.KS ,
South Korea's top biopharmaceutical companies, drop on Monday
after Goldman Sachs forecast deepening competition in the
bioindustry
** Celltrion and Samsung Biologics lose more than 3 pct
each, while Hanmi Pharm 128940.KS tumbles 6.3 pct
** Goldman Sachs cuts Celltrion's target price to 147,000
won ($129.50). Its previous close was 272,000 won. In a report,
the investment bank says competition will come from growing
Chinese and Indian firms
** Following the report, Samsung Biologics halted its
week-long winning streak boosted by Samsung Group's investment
plan
** The broader KOSPI market .KS11 was down 1.5 pct as of
0336 GMT, as the Turkish crisis spreads
($1 = 1,135.1000 won)
((Reuters Messaging:
hayoung.choi.thomsonreuters.com@reuters.net))